Company Overview

Psyched Wellness Ltd. is a Canadian-based life sciences company operating at the intersection of the nutraceutical, functional food, and wellness supplement industries. The company focuses on the research, development, and commercialization of non-psychoactive psychedelic-derived products, with a primary emphasis on the Amanita muscaria mushroom. Unlike classical psychedelics, Amanita muscaria is legal in many jurisdictions and is positioned by the company as a functional wellness ingredient rather than a controlled substance.

The company’s core revenue driver is its flagship consumer product, Calm, a branded, non-psychoactive Amanita muscaria extract marketed as a stress-reduction and relaxation supplement. Psyched Wellness targets health-conscious consumers seeking natural alternatives for stress management, sleep support, and overall mental wellness. Founded in 2020, the company evolved from an early-stage psychedelic research entity into a commercial-stage wellness company following regulatory clearance from the U.S. Food and Drug Administration to sell its extract as a dietary ingredient, enabling entry into the U.S. consumer market.

Business Operations

Psyched Wellness operates through a vertically integrated model encompassing proprietary extraction methods, product formulation, branding, and distribution. Its primary business activity centers on the development and sale of Amanita muscaria-derived products under the Calm brand, which are distributed via direct-to-consumer e-commerce channels and third-party retail platforms. Revenue is generated primarily from product sales rather than clinical services or intellectual property licensing.

Operationally, the company maintains research and product development functions focused on refining extraction technology and ensuring consistency, safety, and scalability. Manufacturing and fulfillment activities are supported through third-party partners, while internal teams oversee quality control, regulatory compliance, and marketing. The company does not currently report multiple operating segments, instead functioning as a single reporting unit centered on consumer wellness products.

Strategic Position & Investments

Strategically, Psyched Wellness positions itself as a first mover in the commercialization of Amanita muscaria-based wellness products, leveraging regulatory permissibility and growing consumer interest in alternative mental wellness solutions. Its growth strategy emphasizes brand expansion, increased retail penetration, and the development of additional Amanita-based formulations beyond its initial product offering.

The company has invested in proprietary extraction technology designed to isolate bioactive compounds while removing ibotenic acid to maintain a non-psychoactive profile. Psyched Wellness has not disclosed material acquisitions or large equity investments in other companies, and public filings indicate a focus on organic growth rather than mergers and acquisitions. Ongoing initiatives include potential line extensions, international market entry, and further validation of its ingredients through scientific research.

Geographic Footprint

Psyched Wellness is headquartered in Canada, with its corporate base in Ontario, and maintains its primary commercial focus in North America. The company’s most significant market is the United States, where its products are legally sold and marketed following regulatory clearance for its Amanita muscaria extract.

While current revenues are concentrated in the U.S. and Canada, the company has indicated interest in expanding into additional international markets where regulatory frameworks permit the sale of functional mushroom supplements. As of the latest public disclosures, Psyched Wellness does not report physical operations or manufacturing facilities outside North America, relying instead on cross-border logistics and third-party service providers.

Leadership & Governance

Psyched Wellness is led by an executive team with experience in capital markets, consumer products, and emerging wellness sectors. The leadership emphasizes disciplined commercialization, regulatory compliance, and shareholder value creation, reflecting the company’s transition from research-focused development to revenue-generating operations.

Key executives include:

• Jeff Stevens – Chief Executive Officer
• Matthew Singh – Chief Financial Officer
• David Shisel – Chief Operating Officer
• Ian McDonald – Chairman of the Board

The board and management team collectively guide corporate strategy, capital allocation, and governance, with a stated focus on transparency, regulatory adherence, and long-term growth within the legal psychedelic-adjacent wellness market.